ポスター3-5 DLBCL/その他：臨床

[PS3-5-6] Cost-effectiveness analysis of tisagenlecleucel for treatment of r/r DLBCL patients in Japan

Shiho Wakase¹, Takanori Teshima², Hikaru Okada¹, Cynthia Qi³, Eric Wu³, Hongbo Yang³, Xinglei Chai³, Yoshinobu Kanda⁴ (1.Novartis Pharma K.K., Minato-ku, Tokyo, Japan, 2.Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan, 3.Analysis Group, Inc., Boston, Massachusetts, United States of America, 4.Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Saitama, Japan)